Burden of Multidrug-Resistant *Acinetobacter baumannii* Infection in Hospitalized Patients in a Tertiary Care Hospital of Nepal

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Santosh Kumar Yadav^{1,2}
Rajshree Bhujel²
Pradip Hamal³
Shyam Kumar Mishra²
Sangita Sharma²
Jeevan Bahadur Sherchand²

¹Department of Microbiology, Rajarshi Janak University, Janakpurdham, Nepal;

²Department of Clinical Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal; ³Department of Pathology, B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal

Introduction: *Acinetobacter baumannii* has emerged as a significant multidrug-resistant (MDR) nosocomial pathogen worldwide and is responsible for various healthcare-associated infections. The MDR strains have been reported increasingly during the last decades in hospitalized patients. They have developed resistance to most of the available antibiotics and are known to produce various acquired β -lactamases. The β -lactamase producing strains have a potential for rapid dissemination in hospital settings, as it is often plasmid-mediated. The Infectious Diseases Society of America (ISDA) stated *A. baumannii* as one of the “red alert” pathogens that greatly threatens the utility of our current antibacterial armamentarium. The study attempted to investigate the spectrum and antimicrobial resistance among MDR *A. baumannii* and their potential implications in hospitalized patients in a tertiary care hospital of Nepal.

Methods: This study was conducted at Tribhuvan University Teaching Hospital (TUTH), Nepal from January 2017 to December 2017. A total of 177 *A. baumannii* isolated from hospitalized patients were included in the study. The AST was performed by disc diffusion method. The MDR strains were identified by the criteria of Magiorakos et al, ESBL production by CLSI guidelines, and AmpC β -lactamase production by the AmpC disc test. MBL and KPC production were detected as per the method of Tsakris et al.

Results: Out of 177 *A. baumannii*, 91.0% were MDR isolates. Among the MDR isolates, the majority were isolated from respiratory tract specimens and were isolated from ICU patients. Most of the MDR isolates were resistant to all first-line antibiotics and all were completely sensitive to only polymyxin B and colistin sulfate. MBL (67.7%) was the common β -lactamase production among MDR isolates.

Conclusion: *Acinetobacter baumannii* can cause a vast variety of infections in hospitalized patients. The highly resistant MDR strains are common in tertiary care hospitals. This bacteria lead to high morbidity and mortality as we are left with the only option of treating them by potentially toxic antibiotics like colistin sulfate and polymyxin B. Detection of drug resistance and rational use of antibiotics play a crucial role in the fight against this MDR pathogen.

Keywords: *Acinetobacter baumannii*, hospitalized patients, multidrug resistant, metallo- β -lactamase

Introduction

Acinetobacter baumannii is an aerobic, non-fermentative, gram-negative, nonmotile, coccobacilli harboring a number of effective virulence factors.¹ The organism is able to survive under a wide range of environmental conditions and persists for extended periods of time on surfaces, which makes them a frequent cause of

Correspondence: Santosh Kumar Yadav
Department of Microbiology, Rajarshi Janak University, Janakpurdham, Nepal
Email: santooshydv@gmail.com

infection outbreak and healthcare-associated infection.² The main problem caused by *A. baumannii* in the hospital setting mostly concerns critically ill patients in intensive care units (ICUs), particularly those requiring mechanical ventilation, and patients with the wound or burn injuries. Infections associated with *A. baumannii* include ventilator-associated pneumonia, skin and soft tissue infections, wound infections, urinary tract infections, secondary meningitis, and blood-stream infections.³

Acinetobacter baumannii has emerged as a significant MDR nosocomial pathogen worldwide and has been reported increasingly during the last decade, probably due to the increasing use of broad-spectrum antibiotics in hospitalized patients.⁴ The Infectious Diseases Society of America (ISDA) stated *A. baumannii* as one of the “red alert” pathogens that greatly threaten the utility of our current antibacterial armamentarium.⁵ Numerous studies have indicated an upward trend in the prevalence of MDR *A. baumannii*, but resistance rates can vary widely according to the individual hospital, city, or country involved. Because MDR *Acinetobacter* infection usually occurs in severely ill patients, the associated crude mortality rate is high, ranging from 26% to 68%.⁶

Multidrug-resistant *A. baumannii* has developed resistance to most of the available antibiotics including carbapenems, which are the drugs of choice in the treatment of severe infections.⁷ The main mechanism for β -lactam resistance in *A. baumannii* corresponds to efflux pumps, porin mutations, and the production of acquired β -lactam hydrolyzing enzymes, ie, Class A (extended-spectrum β -lactamases, ESBLs), class B (metallo- β -lactamases, MBLs), Class C Ampicillinase (AmpC) as well as class D β -lactamases. Carbapenem resistance due to MBL and other carbapenemases production has a potential for rapid dissemination in hospital settings, as it is often plasmid-mediated and early detection of drug resistance is necessary for proper selection of antibiotics to treat *A. baumannii* infections in hospitalized patients and to initiate effective infection control measures to prevent their dissemination in hospital settings.^{8,9}

Keeping the above views in mind, the study was carried out on *A. baumannii* isolated from hospitalized patients to determine their antibiotic susceptibility patterns, to identify MDR strains and to detect various β -lactamases among MDR isolates.

Materials and Methods

The laboratory-based study was conducted at the Department of Clinical Microbiology, Tribhuvan University Teaching

Hospital (TUTH), a tertiary care center of Nepal from January 2017 to December 2017 (over a period of 12 months). All clinical specimens collected from the hospitalized patients suspected with infections representing different body sites (sputum, bronchoalveolar lavage, endotracheal aspirate, pus and swab specimens, different body fluids, urine, blood, catheter tips, etc.) were processed according to standard microbiological methods recommended by American Society for Microbiology (ASM) for isolation and identification of *A. baumannii*.¹⁰

Antibiotic Susceptibility Testing (AST)

The susceptibility of *A. baumannii* isolates against different antibiotics was determined by the modified Kirby–Bauer disk diffusion method on Mueller-Hinton agar and interpreted following standard procedures recommended by the Clinical and Laboratory Standards Institute (CLSI), Wayne, USA.¹¹ The antibiotic sensitivity profile of all the isolates of *A. baumannii* were determined by testing against ampicillin-sulbactam (10/10 μ g), ceftazidime (30 μ g), gentamicin (10 μ g), ciprofloxacin (5 μ g), levofloxacin (5 μ g), meropenem (10 μ g), and imipenem (10 μ g). The isolates that were resistant to at least one antimicrobial from three different groups of above-mentioned antibiotics (ie, MDR isolates) were also tested against piperacillin (100 μ g), piperacillin-tazobactam (100/10 μ g), cefotaxime (30 μ g), cefepime (30 μ g), cotrimoxazole (25 μ g), amikacin (30 μ g), doxycycline (30 μ g), polymyxin B (300 units), and colistin sulfate (10 μ g) from HiMedia Laboratories, India.

Identification of MDR Isolates

Multidrug-resistant *A. baumannii* isolates were identified as per guidelines recommended by the European Centre for Disease Prevention and Control (ECDC). The isolates non-susceptible to at least one antimicrobial agent in three or more antimicrobial classes were identified as MDR.¹²

Detection of Extended-Spectrum β -Lactamase (ESBL) Producers

The initial screening test for the production of ESBL was performed by testing with ceftazidime (CAZ, 30 μ g) and cefotaxime (CTX, 30 μ g) disks. The isolates were considered as potential ESBL producers when the zone of inhibition (ZOI) was either <18 mm for CAZ or <23 mm for CTX. Isolates that were suspected as ESBL

producer by screen test were tested further by combination disk (CD) method for confirmation of ESBL production, in which CAZ and CTX alone and in combination with clavulanic acid [(CAZ+CA, 30/10 µg), (CTX+CA, 30/10 µg)] were used. After incubation for 16–18 hrs at 35±2°C, an increase in ZOI of ≥5 mm for either antimicrobial agent in combination with clavulanic acid than its inhibition zone when tested alone, was confirmed as positive ESBL producers.¹¹

Detection of AmpC β-Lactamase Producers

Acinetobacter baumannii producing a zone of inhibition <18 mm for cefoxitin (CX, 30 µg) disk was tested for AmpC β-lactamase production. AmpC β-lactamase was detected by the AmpC disk test. In this method, cefoxitin susceptible *Escherichia coli* indicator strain (ATCC 25922) was inoculated on standard MHA plate to form a lawn culture and a cefoxitin disk was placed. A blank disk of 6 mm diameter moistened with Tris-EDTA buffer was inoculated with few colonies of test strain and placed next to the cefoxitin disk. The plates were incubated at 37°C overnight. After overnight incubation, an indentation in the cefoxitin inhibition zone adjacent to the disk containing test strain was considered positive for AmpC β-lactamase production.¹³

Detection of Metallo β-Lactamase (MBL) and *Klebsiella pneumoniae* Carbapenemase (KPC) Producers

The isolates were subjected to detection of MBL and KPC production when resistant to meropenem (MEM, 10 µg). The combination meropenem disk method was applied for detection and differentiation of MBL, KPC or co-producer of KPC/MBL as described by Tsakris et al¹⁴ In this test, four disks were used; (a) MEM = a plain MEM disk (10 µg), (b) MEM+EDTA = MEM disk (10 µg) with 292 µg of EDTA, (c) MEM+phenylboronic acid (PBA) = MEM disk (10 µg) containing 400 µg of PBA, and (d) MEM+EDTA+PBA = MEM disk (10 µg) with both 292 µg of EDTA and 400 µg of PBA. The EDTA acts as an inhibitor of MBL while PBA is a KPC inhibitor. The test was performed by inoculating a Mueller–Hinton agar with test organism as given for the standard diffusion method and four disks were applied. After incubation of overnight at 37°C, the ZOI diameter around MEM+EDTA, MEM+PBA, and

MEM+EDTA+PBA disks was compared with that around the plain MEM disk. Production of MBL was considered when the ZOI diameter around the MEM+EDTA and MEM+EDTA+PBA disks was increased ≥5 mm than ZOI diameter around the MEM disk alone. Production of KPC was considered when the ZOI diameter around the MEM+PBA and MEM+EDTA+PBA disks was increased ≥5 mm than ZOI diameter around the MEM disk alone. The co-production of both KPC and MBL enzymes was considered when the ZOI diameter around the MEM+EDTA+PBA disks was increased ≥5 mm than ZOI diameter around the MEM disk alone. It should be noted that the concentration of PBA and EDTA employed in the present study did not show any detectable effect on bacterial growth.

Data Processing and Analysis

Data regarding patient demographics, specimens, wards, antibacterial profiles, resistance determinants were analyzed using SPSS 16.0 version and interpreted according to frequency distribution and percentage.

Results

During the study period, a total of 177 *A. baumannii* were isolated. Out of the total *A. baumannii* isolates, most of them (N=161, 91.0%) were identified as MDR.

Distribution of MDR *Acinetobacter baumannii*

Out of 161 MDR isolates, the majority (47.2%) were isolated from respiratory tract specimens (ie, sputum, bronchoalveolar lavage, and tracheal aspirate) followed by pus and swabs, body fluids, urine, blood and least were from catheter tips (1.2%) (Table 1). Among total MDR isolates, 58.3% were isolated from male and 41.7% were from female patients, with male to female ratio 1.4. The highest number of isolates were from male patients with age group ≥65 years (14.9%) and the least number was isolated from a female patient with age group 49–64 years (5.0%) (Table 2). Similarly, the higher number of MDR isolates were isolated from ICU patients (49.6%) followed by surgical wards (19.9%) and medical wards (14.3%), while the lowest number from burn wards (1.9%) (Table 3).

Table 1 Distribution of MDR *Acinetobacter baumannii* in Various Clinical Specimens

Specimens	Number	Percentage
Respiratory tract specimens	76	47.2
Pus and swabs	44	27.3
CSF and other body fluids	18	11.1
Urine	11	6.8
Blood	10	6.2
Catheter tips	2	1.2
Total	161	100

Table 2 Distribution of MDR *Acinetobacter baumannii* by Gender and Age Group of Patients

Age Group	Number (%)		Total Number (%)
	Female	Male	
≤15 Years	16 (9.9)	16 (9.9)	32 (19.8)
16–32 Years	18 (11.2)	20 (12.4)	38 (23.6)
33–48 Years	13 (8.1)	17 (10.6)	30 (18.7)
49–64 Years	8 (5.0)	17 (10.5)	25 (15.5)
≥65 Years	12 (7.5)	24 (14.9)	36 (22.4)
Total number (%)	67 (41.7)	94 (58.3)	161 (100)

Table 3 Ward Wise Distribution of MDR *Acinetobacter baumannii*

Wards	Number of MDR Isolates	Percentage
ICUs	80	49.6
Surgical	32	19.9
Medical	23	14.3
Orthopedics	9	5.6
Pediatrics	6	3.7
Maternity	4	2.5
Ophthalmology	4	2.5
Burn	3	1.9
Total	161	100

Antibiogram of MDR *Acinetobacter baumannii*

The antibiotic sensitivity profile shows that most of the MDR isolates were resistant to the majority of first-line antibiotics. Among them, all isolates were completely resistant to piperacillin and cefotaxime. Similarly, 99.4% were resistant to ceftazidime and cefepime, 98.7% to cotrimoxazole, 95% to piperacillin-tazobactam and ciprofloxacin, 93.8% to gentamicin, 89.4% resistant to ampicillin-sulbactam and meropenem. Only 11.8%, 12.4%, 13.6%, and 37.9% were sensitive to levofloxacin, imipenem, amikacin, and doxycycline, respectively. All the

MDR isolates were completely sensitive to only last resort antibiotics, ie, polymyxin B and colistin sulfate (Figure 1).

ESBL, AmpC, MBL, and KPC Production in MDR *Acinetobacter baumannii*

In this study, the rate of β -lactamases production among MDR isolates was significantly high. MBL was the common β -lactamase detected among MDR *A. baumannii* (67.7%). ESBL was detected in 19.9%, AmpC in 38.5%, and KPC in 9.3% of MDR isolates. The co-production of different types of β -lactamases was also seen among some isolates. ESBL+AmpC co-producers were seen in 6.8%, ESBL+MBL co-producers in 5.0%, AmpC+MBL co-producers in 23.0% and MBL+KPC in 5.6% of MDR isolates (Table 4).

Discussion

Acinetobacter baumannii is an important nosocomial pathogen associated with a wide variety of illnesses in hospitalized patients especially in the intensive care units imposing a greater challenge to the patient's management and infection control. The worldwide emergence of MDR *A. baumannii* isolate is of great concern.¹⁵

In our study, MDR *A. baumannii* was frequently isolated from respiratory tract specimens (47.2%), followed by pus and swabs (27.3%), body fluids (11.1%) and others. A study was done by Shrestha et al in 2015¹⁵ from the same hospital also reported 49.18% of MDR *A. baumannii* from respiratory tract specimens and Samawi et al¹⁶ from Qatar reported 48.9% *A. baumannii* from respiratory tract infection. The demographic data in our study showed that a high prevalence of infections in male patients having age ≥65 years and a major of MDR isolates were from ICU patients because this bacteria have a predilection for higher age groups and severely ill ICU patients.

The rate of MDR *A. baumannii* in our study is 91.0% which is extensively high. Also in the study done by Shrestha et al and Mishra et al, around 96% and 95% of *A. baumannii* were MDR, respectively.^{17,18} This high prevalence of MDR *A. baumannii* may be due to the high chance of dissemination of resistance gene and their ability to present everywhere in the hospital environment. The *A. baumannii* infection with high MDR isolates has also alarmed us that there is further need for extensive study and application of preventive measures to reduce such a fearful threat in hospitalized patients. Multidrug-resistant *A. baumannii* isolates were found significantly resistant to carbapenems, aminoglycosides, and fluoroquinolone groups of antibiotics in this study. Almost all the MDR isolates

Figure 1 Percentage of antimicrobial resistance and sensitivity of MDR *A. baumannii* (N = 161).

were resistant to piperacillin and cephalosporins, 93.8% resistant to gentamycin and 89.4% to meropenem which is higher than that reported by Mishra et al¹⁸ from the same hospital (nearly 89% and 50% isolates were cephalosporins and carbapenem-resistant, respectively). A study conducted by Xia et al in China demonstrated carbapenem resistance in 85% of isolates which is nearly similar to this study.¹⁹ The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) program of 2007 demonstrated that 74.1% of isolates were susceptible to meropenem and 78.9% were susceptible to imipenem in Europe, compared with much lower susceptibilities of 51.3% and 52.0% in several Asian countries.^{20,21} Our result on the resistance rate to amikacin

was 86.3% which is higher than 54% in the previous study from the same hospital.¹⁸ The increasing emergence of highly aminoglycosides resistant strains is also the cause of major concern. In this study, 95.0% and 88.2% MDR *A. baumannii* were resistant to ciprofloxacin and levofloxacin, respectively. The fluoroquinolone resistance is increasing rapidly in clinical isolates in recent years because of their wide use in clinical medicine as broad-spectrum antimicrobial agents. In our study, polymyxin B and colistin sulfate showed excellent effect against MDR *A. baumannii* as none of the isolates was found resistant to colistin sulfate and polymyxin B. But, in the study of Joseph et al²² and Al-Sweih et al,²³ 20% and 12% *Acinetobacter* spp. were resistance to colistin sulfate, respectively. However, the present study has showed a high antibiotic resistance rate against commonly used antibiotics and is a disadvantage for the health-care system in countries like Nepal as it can greatly affect patient management. This may be because of the intense use of the antimicrobial agents in the hospital, easy availability, and indiscriminate use of these drugs outside the hospitals, and many antibiotics are available over the counter for self-medication. The development of antibiotic resistance is associated with high morbidity and mortality in hospitalized patients, particularly in ICU settings.

The decreased susceptibility of *A. baumannii* towards the third generation and fourth-generation cephalosporins could be attributed to ESBL or AmpC β -lactamase producers or

Table 4 β -Lactamases Production Among MDR *Acinetobacter baumannii*

Types of β -Lactamases	Number	Percentage
ESBL	32	19.9
AmpC	62	38.5
MBL	109	67.7
KPC	15	9.3
Co-Producers		
ESBL + AmpC	11	6.8
ESBL + MBL	8	5.0
AmpC + MBL	37	23.0
MBL + KPC	9	5.6

some other relevant underlying mechanisms. This study showed 19.9% of the MDR *A. baumannii* was ESBL-producer. A similar rate of ESBL was found in a previous study by Parajuli et al in ICU patients.²⁴ In the study of Mishra et al,¹⁸ only 12.9% of *Acinetobacter* spp. were ESBL producers. In an Indian study,²⁵ only 7% *A. baumannii* isolates were ESBL producers, while another study from India⁸ documented 29.9% of *Acinetobacter* spp. as ESBL producers. Studies have demonstrated that the prevalence of ESBL varies from country to country and institution to institution in both nosocomial and community isolates. This may be ascribed to antibiotic prescribing habits and the presence of pathogens harboring the genes for ESBL production. Although there are no CLSI guidelines for the detection of the AmpC β -lactamases production, we have followed AmpC disk test.¹³ In the present study, the prevalence of AmpC producing MDR *A. baumannii* was found 35.6%. Almost a similar prevalence of AmpC producing *Acinetobacter* spp. have been reported from the same hospital by Parajuli et al²⁴ However, in an Indian study, the higher rate (56%) of AmpC producing *A. baumannii* was documented.²⁶

Carbapenem-resistant *Acinetobacter baumannii* (CRAB) is included in priority 1 (ie, critical) of a global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new drugs by the World Health Organization.²⁷ Although there are different mechanisms for carbapenem resistance, the production of carbapenemases enzyme is the most effective mechanism.⁹ The emergence of MBLs in *A. baumannii* is becoming a therapeutic challenge as these enzymes possess high hydrolytic activity that leads to degradation of higher generation cephalosporins and carbapenems. Furthermore, plasmid-mediated MBL genes spread rapidly to other species of gram-negative bacilli.²⁸ Therefore, rapid detection of MBL production is necessary to modify therapy and to initiate effective infection control to prevent their dissemination. In the current study, metallo β -lactamase (MBL) producing isolates were found common than ESBL and AmpC producers, where 67.7% MDR *A. baumannii* were MBL producers. In Nepal, few studies have been done on the prevalence of MBLs, Shrestha et al²⁹ reported 47.2% and Parajuli et al²⁴ reported 78.8% MBL producers in *Acinetobacter* spp. from the same hospital. In the study of Dey and Bairy,³⁰ MBL was reported only in 21.7% of *Acinetobacter* spp. The coexistence of multiple MBL genes in bacteria is an alarming situation. As MBL genes are associated with integrons that can be embedded in transposons, which in turn can be

accommodated on plasmids thereby resulting in a highly mobile genetic apparatus, the further spread of these genes in different pathogens is likely to occur. This study also attempted to find out the KPC-producing isolates, where 9.5% MDR *A. baumannii* and some of them were also co-producing MBL enzyme. Although there was no single article regarding the detection of KPC from Nepal, Parajuli et al²⁴ recently reported KPC-producing *Acinetobacter* species from ICU patients. Most of the KPC-producing isolates have been reported from the USA, Greece, China, Israel, and Colombia.³¹ Among carbapenemases, KPC has a high frequency and has been commonly found in *Klebsiella pneumoniae*.³² Among the β -lactamases producing isolates, some of the isolates were also co-producers of different β -lactamases and the MDR isolates producing two different types of β -lactamases showed high resistant profile. The spread of carbapenemase-producing bacteria throughout the world in recent years has been considered as a major threat to public health. After the carbapenem-resistant clones have emerged, leaving the hope of treatment of MDR *A. baumannii* infection is by the last resort of potentially toxic antibiotics such as polymyxin B and colistin sulfate.³³

The study shows infection with MDR *A. baumannii* is increasing at an alarming rate in our hospital. It has now become very important to control this situation before it takes a deadly shape. Therefore, rapid detection of the resistance determinants is necessary to modify therapy and to initiate effective infection control to prevent their dissemination.

Limitations

We could not evaluate the risk factors and outcomes of MDR *A. baumannii* infections in hospitalized patients due to the unavailability of sufficient data from the patients. Furthermore, genetic analysis of the resistant phenotypes and drug resistance mechanisms was not determined.

Conclusion

From the present study, it is clear that infections in hospitalized patients due to MDR *A. baumannii* are common. Rate of MBL, ESBL, and AmpC production among MDR isolates has highly increased and this bacteria may lead to high morbidity and mortality as we are left with the only option of treating them by potentially toxic antibiotics like colistin sulfate and polymyxin B and this is the vexatious problem for hospitalized patients. Established recommendations including proper detection of drug resistance in pathogens, antimicrobial restriction policies to avoid

excessive use of broad-spectrum antibiotics, improving resistance surveillance systems, and rigorous infection control measures will help to control this situation.

Abbreviations

AmpC, ampicillinase C; ASM, American Society for Microbiology; CLSI, Clinical and Laboratory Standard Institute; ESBL, extended-spectrum β -lactamases; EDTA, ethylene-diamine-tetraacetic acid; ICU, intensive care unit; KPC, *Klebsiella pneumoniae* carbapenemase; MBL, metallo β -lactamases; MDR, multidrug resistant; PBA, phenylboronic acid; SPSS, statistical package for the social sciences; TUTH, Tribhuvan University Teaching Hospital.

Ethical Approval and Consent to Participate

Written approval (Ref No: 262(6-11-E)2/073/074) was obtained from the Institutional Review Board (IRB) of the Institute of Medicine after submitting and presenting a research proposal. In addition, written consent was taken from every patient or their guardian for participation in this study before enrollment.

Data Sharing Statement

Primary data regarding this report will be made available to the interested researchers upon written request.

Acknowledgments

The authors would like to offer their sincere gratitude to all faculties and staffs of the Department of Clinical Microbiology and staffs of different wards of Tribhuvan University Teaching Hospital.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Authors' Information

Santosh Kumar Yadav: Department of Microbiology, Rajarshi Janak University, Janakpurdham, Nepal.

Rajshree Bhujel, Shyam Kumar Mishra, Sangita Sharma and Jeevan Bahadur Sherchand: Department of Clinical Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.

Pradip Hamal: Department of Pathology, B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal.

Funding

No funding source was involved to complete this study.

Disclosure

The authors declare that they have no conflicts of interest in this work.

References

1. Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant *Acinetobacter baumannii* infection in a surgical intensive care unit. *Infect Control Hosp Epidemiol*. 2007;28(11):1247–1254. doi:10.1086/521660
2. Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis*. 2008;46(8):1254–1263. doi:10.1086/529198
3. Van Looveren M, Goossens H, Baquero F, et al. Antimicrobial resistance of *Acinetobacter* spp. in Europe. *Clin Microbiol Infect*. 2004;10(8):684–704. doi:10.1111/j.1469-0691.2004.00942.x
4. Towner KJ. *Acinetobacter*: an old friend, but a new enemy. *J Hosp Infect*. 2009;73(4):355–363. doi:10.1016/j.jhin.2009.03.032
5. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev*. 2008;21(3):538–582. doi:10.1128/CMR.00058-07
6. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant *Acinetobacter* infection mortality rate and length of hospitalization. *Emerg Infect Dis*. 2007;13(1):97–103. doi:10.3201/eid1301.060716
7. Garnacho-Montero J, Amaya-Villar R. Multiresistant *Acinetobacter baumannii* infections: epidemiology and management. *Curr Opin Infect Dis*. 2010;23(4):332–339. doi:10.1097/QCO.0b013e32833ae38b
8. Tripathi P, Gajbhiye S. Prevalence of multidrug resistance, ESBL and MBL production in *Acinetobacter* spp. *Int J Recent Trends Sci Technol*. 2013;6(3):139–143.
9. Noyal MJC, Menezes GA, Harish BN, Sujatha S, Parija SC. Simple screening tests for detection of carbapenemases in clinical isolates of nonfermentative Gram-negative bacteria. *Indian J Med Res*. 2009;129(6):707–712.
10. Isenberg H. *Clinical Microbiology Procedure Handbook*. 2nd ed. Washington, DC: American Society for Microbiology (ASM); 2007.
11. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing, Supplement M100S*. 26th ed. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2016.
12. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
13. Singhal S, Mathur T, Khan S, et al. Evaluation of methods for AmpC β -Lactamase in gram negative clinical isolates from tertiary care hospitals. *Indian J Med Microbiol*. 2005;23(2):120–124. doi:10.4103/0255-0857.16053
14. Tsakris A, Poulou A, Pourmaras S, et al. A simple phenotypic method for the differentiation of metallo- β -lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. *J Antimicrob Chemother*. 2010;65(8):1664–1671. doi:10.1093/jac/dkq210
15. Shrestha S, Tada T, Shrestha B, et al. Phenotypic characterization of multidrug-resistant *Acinetobacter baumannii* with special reference to metallo- β -lactamase production from the hospitalized patients in a tertiary care hospital in Nepal. *JIOM*. 2015;37(3):3–10.

16. Saad M, Samawi A, Khan FY, et al. *Acinetobacter* infections among adult patients in qatar: a 2-year hospital-based study. *Canadian J Infect Dis Med Microbiol.* 2016. doi:10.1155/2016/6873689
17. Shrestha RK, Dahal RK, Mishra SK, et al. Ventilator-associated pneumonia in tertiary care. *JJOM.* 2013;35(3):21–28.
18. Mishra SK, Rijal BP, Pokhrel BM. Emerging threat of multidrug resistant bugs – *acinetobacter calcoaceticus baumannii* complex and Methicillin-resistant *Staphylococcus aureus*. *BMC Res Notes.* 2013;6(1):1. doi:10.1186/1756-0500-6-98
19. Xie D, Xiong W, Lai R, et al. Ventilator-associated pneumonia in intensive care units in Hubei Province, China: a multicentre prospective cohort survey. *J Hosp Infect.* 2011;78(4):284–288. doi:10.1016/j.jhin.2011.03.009
20. Villegas MV, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum beta-lactamases in South America. *Clin Microbiol Infect.* 2008;14 Suppl 1:154–158. doi:10.1111/j.1469-0691.2007.01869.x
21. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, –24/40 and –58 carbapenemases among *Acinetobacter* spp. in Asia-Pacific nations: report from the SENTRY surveillance program. *J Antimicrob Chemother.* 2009;63(1):55–59. doi:10.1093/jac/dkn434
22. Joseph NM, Sistla S, Dutta TK, Badhe AS, Rasitha D, Parija SC. Ventilator-associated pneumonia in a tertiary care hospital in India: role of multidrug resistant pathogens. *J Infect Dev Ctries.* 2010;4(4):218–225. doi:10.3855/jidc.634
23. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in *Acinetobacter* species isolated from patients in Kuwait hospitals. *J Chemother.* 2011;23(1):13–16. doi:10.1179/joc.2011.23.1.13
24. Parajuli NP, Acharya SP, Mishra SK, Parajuli K, Rijal BP, Pokhrel BM. High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal. *Antimicrob Resist Infect Control.* 2017;6(1):67. doi:10.1186/s13756-017-0222-z
25. Safari M, Sasan A, Nejad M, Bahador A. Prevalence of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). *Saudi J Biol Sci.* 2015;22(4):424–429. doi:10.1016/j.sjbs.2015.01.004
26. Hans R, Bisht D, Agarwal R, Medical S. Phenotypic detection of MBL, AmpC beta-lactamase and carbapenemases in multi drug resistant isolates of *Acinetobacter baumannii*. *Int J Med Res Heal Sci.* 2014;4(2):311–316. doi:10.5958/2319-5886.2015.00058.2
27. Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. *World Heal Organ.* 2017;27:1–7.
28. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. *Lancet Infect Dis.* 2011;11(5):355–362. doi:10.1016/S1473-3099(11)70059-7
29. Shrestha S, Chaudhari R, Karmacharya S, et al. Prevalence of nosocomial lower respiratory tract infections caused by Multidrug resistance pathogens. *JJOM.* 2011;33(2).
30. Dey A, Bairy I. Incidence of multidrug-resistant organisms causing ventilator-associated pneumonia in a tertiary care hospital: a nine months' prospective study. *Ann Thorac Med.* 2007;2(2):52–57. doi:10.4103/1817-1737.32230
31. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis.* 2013;13(9):785–796. doi:10.1016/S1473-3099(13)70190-7
32. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of *Pseudomonas aeruginosa* isolates producing a KPC-type carbapenem-hydrolyzing β -lactamase. *Antimicrob Agents Chemother.* 2007;51(4):1553–1555. doi:10.1128/AAC.01405-06
33. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β -lactamase VEB-1-producing isolates of *Acinetobacter baumannii* in a French hospital. *J Clin Microbiol.* 2003;41(8):3542–3547. doi:10.1128/JCM.41.8.3542-3547.2003

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>